I'he protective value of pooled human gamma globulin (GG) and a group B streptococcal immune globulin (GBSIG) was studied in a chick embryo and a murine model of group B streptococcal (GBS) infection. Chick embryos were protected by the I V administration of 0.4 to 0.8 mg of GG from three manufacturers against I V challenge with type l a GBS. Two of three G G preparations at doses of 0.4 to 1.65 mg protected chick embryos against type 111, but 1.65 mg of all three preparations failed to protect against GBS types I b and 11. Mice were protected from lethal I P challenges with types l a and I b by the prior IM inoculation of three and two of the three GG preparations at doses of 0.5 to 1.0 mg, respectively. Administration IM of 1 mg of GG failed to protect mice against types 11 and 111.
Group B streptococci (GBS) are major bacterial pathogens in early infancy ( 1). Despite appropriate antimicrobial therapy, neonatal GBS infections are associated with a high morbidity and mortality. suggesting that efforts be directed toward prevention of these infections by active or passive immunoprophylaxis (9) . One predisposing factor in the development of neonatal GBS infections is low concentrations of maternal transplacentally acquired, typespecific antibody (3, 4, 7, 21) . Therefore. active immunization of women of childbearing age would be an ideal approach in preventing neonatal GBS infections. Baker et al. (2) have described a native type I11 carbohydrate antigen as a potential vaccine, and preliminary studies in adult volunteers have shown that this vaccine is immunogenic and safe.
Until vaccines for each of the five GBS types have been developed and administered to the susceptible childbearing population. passive immunization might be used to prevent neonatal GBS infections. Hyperimmune and pooled human gamma globulin ( G G ) have been used with variable success in the prophylaxis and treatment of several viral and bacterial infections ( 17) . Passi\ immunization of pregnant women or newborn infants m~ght prc vide protection to the infant during the first few months of life. 1 addition, passive immunization might be effective in preventin recurrent GBS infections and may be a useful adjunct to antibiot therapy. have demonstrated that poole G G at a dose as low as 0.3 ml/kg IM protected mice from lethi IP challenges with type la GBS. These investigations have bee extended to include G G from three different manufacturers an passive protection studies in both mice and chick embryos usin GBS types la. Ib. 11, and 111. Protection studies in mice and chic embryos were also performed using a group B streptococci immune globulin (GBSIG). which was prepared fiom human ser with high titers of type-specific IgG antibody.
MATERIALS A N D METI1OI)S P R t P A R A T l O N OF HAC'TERIA
GBS Ia-SShl5 (type la) was obtained from the Center f o~ Disease Control and was passed 2X times in atlult mice nnc designated la-SS615/2X ( I I). Mouse-passaged strains Ib-H36B/ 60/2 (type Ib) and 11-18RS21/67/1 (type 11) were kindly suppliec by Dr. Rebecca Lancefield. GBS Ib-Grav. 111-And. 111-Bell. 111. Daw, 111-Grif. and 111-Heat were isolated from infants with GBS infections.
Bacteria were grown at 37°C to midlogarithmic phase (optical density of 0.30 at 550 nm) in Todd-Hewitt broth containing 0.5p+ dextrose. Aliquots were frozen in an acetonedry ice bath and stored at -70°C until used. Viability and concentrations of bacteria (cfu/ml) were determined for each experiment by spread plating on trypticase soy:53 defibrinated sheep blood agar plates. Hyperimmune rabbit anti-GBS type Ill sera were prepared by immunizing adult male New Zealand White rabbits IV with a Sormalinized whole cell vaccine of Ill-Bell ( I I). Human sera used in passive protection studies in mice were obtained from healthy women and were frozen in I-ml aliquots at -70°C until used. The human sera were heat inactivated at 56°C for 30 min before use.
The GBSIG was prepared by pooling human sera from five adult volunteer blood donors with high titers of antibody against GBS serotypes. Each of the sera had type-specific IgG antibody PROTECTIVE VALUE 01: GG PREPARATIONS 78') easured by an indirect immunofluorescent ( I F ) assay to at least le of the GBS serotypes and had titers that were at least twice e min~mum titer required for chick embryo protection (21). The ra were pooled in equal amounts, and the IgG fraction was 3tained by (NH4)2S0.t precipitation and DEAE-cellulose chroatograph; (8). Using membrane filtration (CF5OA membrane Ines; Amicon Corp.. Lexington, MA), the GBSlG was concenated to a protein concentration of I to 5 g/100 ml as determined y the Biuret reaction. Purity of GBSlG was demonstrated by !~nlunoelectrophoresis.
The IF assay for type-specific Igti antibody to each ofthe GBS :rolypes utilizes acetone-fixed whole bacteria on slides and mono~ecific rabbit antihuman IgG conjugated with fluorescein isothiLyanate (2 1 ). mg of G G or 0.03 to 4.8 mg of GBSlG in 0. I ml. 0. l to 0.5 ml of human serum, or 0.05 rnl of rabbit anti-Ill serum 1M 24 hr prior to lethal IP challenge with GBS. lnocula that consistently produced greater than 90%' mortality were used. Protection studies in mice with Ill-Bell were also performed inoculating 0.2 ml of undiluted human sera or 0.125 mg to I mg of G G or GBSlG IP simultaneously with the IP challenge with 111-Bell. Deaths were monitored for three days after the bacterial challenge.
At least four chick embryos or mice were given injections of each dilution of G G or human sera and type of GBS tested. The mean number of chick embryos tested per dilution of G G for each of the GBS types was 8, and the mean number of mice tested was 6.5. Protection was designated if at least 75% of chick embryos or mice survived the bacterial challenge. Controls for each experiment included injection of PBS. bacteria. G G , and protective or nonprotective human sera with bacteria.
ANIMAI. STU1)lES RESULTS
Twelve-day-old chick embryos were inoculated IV with 0.1 ml f a mixture contain~ng equal volumes of a lethal inoculum of iBS diluted in phosphate-buffered saline, pH 7.2 (PBS) and G G r GBSlG (18). The 50':i lethal dose (LD:,l) and Y0"i lethal dose LD!",) for la-SS615/2X. lb-H36B/60/2. 11-18RS21/67/1. and 111-;ell have been reported previously (18. 21). The LD:,,' and LD:nl f 111-And. 111-Daw. Ill-Grif, and Ill-Heat were determined by robit analysis of dose mortality curves established by IV inoculaon of ch~ck embryos with increasing numbers of bacteria in 0.1 11. The inoculum of GBS used in passive protection studies in The bacterial inoculum that consistently produced greater than 0"; mortality in 21-day-old mice was established by 1P injection rf increasing numbers oflb-Grav. Ib-H36B/60/2, and 11-1 8RS2I/ 17/1 in 0.2 ml of PBS, Ill-Bell. and Ill-Daw in 1.0 ml of heart nfusion ( H I ) broth with 5':; defibrinated sheep blood (5) . Passive mtection studies in 2 I-day-old mice challenged with la-SS6 15/ !X have been described previously (15). Mice received 0.25 to I The LD,, and LD!xl in 12-day-old chick embryos for the type 111 GBS strains, Ill-And. 111-Daw, Ill-Grif. and Ill-Heat, are shown in Table I . Susceptibility of 2 I-day-old mice to IP challenge with CiBS Ib-Grav. lb-H36B/60/2, 11-IXRS21/67/1, 111-Bell, and
Ill-Daw is shown in Table 2 .
The minimal amount of G G or GBSlG necessary to protect chick embryos against GBS types la. Ib, 11. and 111 is shown in Table 3 . Protection studies were not performed with type Ic GBS because of our previous finding that protection of chick embryos by human sera is nearly identical for types Ia and Ic (21) . Chick embryos were protected against IV challenges with type Ia-SS615/ 28 by the simultaneous 1V administration of all three G G preparations at doses of 0.4 to 0.8 mg. For types Ib-H36B/60/2 and II-18RS21/67/1. 1.65 mg of all three G G preparations failed to protect chick embryos. G G from two of three manufacturers protected chick embryos against type Ill-Bell at doses of 0.4 and 1.65 mg.
Mice inoculated IP with type la GBS were protected by the IM administration of 0.5 to 1.0 mg of all three G G preparations (Table 4) . For type Ib-H36B/60/2, mice were protected by two of three G G preparations given IM at doses of 0.5 and 1.0 mg. Because the LD,,, of Ib-H36B/60/2 inoculated IP into mice was Table I . Su.sceptihi11f~~ ofI2-do!-old chick ernhrvos to !,pe 111 GBS However, none of the GG preparations inoculated IP at a dose I 1 mg protected mice against simultaneous IP challenge with 11 Bell. Because none of the three G G preparations protected mice ( chick embryos against all four GBS serotypes tested, a GBSIt was prepared from selected immune human donors. Rec~procal titer or individual human serum.
' Antihody not detected in und~luted sera hy IF Reciprocal titers of a 16.Sr; preparation ofGRSI<i.
gainst lethal IV challenges with all strains of the tbur GBS types :sled. The IM administration of GBSIG protected mice against IP hallenges with types la. Ib. and I1 GBS strains at doses from 0.03 : , 0.5 mg. As much as 4.8 mg of GBSIG administered IM failed 3 protect mice challenged IP with 111-Bell. The IM administration f up to 0.5 ml of a human serum with an IF antibody titer to ype I11 of 1:640 also failed to protect mice against IP challenge vith 111-Bell. with four of eight mice surviving. In contrast. 0.05 nl of hyperimmune rabbit anti-Ill serum administered IM proected all four mice against subsequent IP challenge with Ill-Bell. astly, the simultaneous administration of 0.25 mg of GBSIG vith 111-Bell IP protected all b u r mice tested.
Until an effective and safe vaccine is developed and distributed br all five GBS types. passive immunizatio; could be a useful llternative for the prevention of neonatal GBS infections. EarlyInset GBS infections could be prevented by the administration of > G to mothers or neonates in pregnancies associated with a high isk of neonatal GBS infections ( I . 16). Because early-onset GBS nfections are often acquired in utero ( I , 16) . administration of 3 G to the mother prior to or during labor may be useful in ,reventing or attenuating these infections. Alternatively. passive mmunization could be given at birth to neonates who are at high .isk of developing early-onset GBS infections. Because recurrent 3BS infections in neonates have been a problem (6. 19. 22) . Iassive immunization may be worthwhile i n preventing recur--ences after completion of antimicrobial therapy. Passive immulization may also be of value in the prevention of late-onset CjBS nfections in colonized infants who lack protective levels of typeipecific antibody.
Despite appropriate antibiotics, the mortality of early-onset 3 B S infections is approximately 50% ( I ) . Shigeoka et al. (14) have presented preliminary data suggesting benefit from transfusing ~nfants with fresh whole blood containing heat-stable. type-spe-:ific opsonins in the therapy of early-onset GBS infections. All nine neonates who received blood containing antibody to their ~nfecting strains survived. but only three of six infants survived who were transfused with blood lacking homologous type-specific antibody. An increase of type-specific opsonic activity was only observed in neonates who received a transfusion of at least 40% of their blood volume. Similarly. G G could also be used as an adjunct to antibiotic and supportive therapy in GBS infections.
The advantages include administration to small neonates In acceptable volimes. thus avoiding transfusion. and a defined antibody content.
We have evaluated prophylactic G G and GBSlG in two experimental animal models of GBS infection. G G from each of three manufacturers failed to uniformly protect chick embryos or mice against lethal infections with all of the four GBS types tested. This result was not surprising because we have found that only a small percentage of sera from adults possess type-specific IgG antibody which protects chick embryos ( 2 0 ) . Therefore. GBSIG was prepared from selected immune donors.
The simultaneous IV inoculation of GBSIG with GBS-protected chick embryos against all strains of the four GBS types tested. To estimate the amount of GBSIG in a human neonate that is equivalent to the protective dose of GBSlG in the chick embryo. we assumed blood volumes of 1.5 ml in 12-day-old chick embryos (13) and 85 ml/kg in human newborns (12). Inasmuch as the blood volume per kg in human newborns is approximately 60 times greater than in chick embryos. GBSIG. I2 mg/kg (0.07 nil/kg of a 16.5 g V preparation) would be roughly equivalent to 0.2 mg of GBSlG that is protective in chick embryos agatnst each of the-four types tested.
Mice were protected against lethal 1P challenges with types Ia. Ib, and 11 GBS by the IM administration of0.5 mg of CiBSIG. In contrast, IM administration of4.X mg of GBSlG failed to protect mice against IP challenges with type 111 GBS. and protection was observed only when GBSIG was administered simultaneously IP with 111-Bell or when hyperimmune rabbit sera was given IM. The inability of IM-administered GBSlG to protect mice challenged IP with 111-Bell may be explained by differences in murine resistance to type 111 GBS (10). Because the mean weight of the mice was 10 g. the IM dose of GBSIG was 50 mg/kg or 0.3 nil/kg of a 16.5 if%) preparation for protection agains; types la, Ib, and 11.
The four-fold increase in GBSlG needed to protect mice compared to chick embryos probably reflects the differences in the route and timing of adrninistration. Protection was more readily attained when GG was mixed with bacteria immediately before IV injection into chick embryos than the IM administration of CiCi 24 hr prior to IP bacterial challenge in mice.
These studies indicate that a hyperimmune globulin may be effective in preventing human infections with all of the CiBS serotypes. Our results also suggest that, along with obvious theoretical advantages, an IV preparation would be superior, but en~yme-treated IV G G has not been approved for routine use. CiBSICi is a potentially useful agent in preventing neonatal GBS infections, as well as a possible adjunct to antibiotic and supportive therapy of severe GBS infections. These studies demonstrating effectiveness in two animal models of GBS infections justify tr~als in human neonates.
